Triple Therapy Enhances Glycemic Control in Cystic Fibrosis Patients with Abnormal Glucose Tolerance
Elexacaftor-tezacaftor-ivacaftor significantly improves glucose tolerance, lowers A1c and sweat chloride levels, and demonstrates safety in cystic fibrosis patients with impaired glucose tolerance or cystic fibrosis-related diabetes over 48 weeks.